ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

ZLAB vs VRDN // OPTIONS IMPLIED MOVE & PUT/CALL SKEW

Zai Lab Limited (NASDAQ) VS. Viridian Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: ZLAB 2 — VRDN 2
■ METRIC PARITY
options-implied-move
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ZLAB VS. VRDN) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC ZLAB VRDN SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 58.30% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield -6.33% -9.85% +3.52 ZLAB /fcf-yield <GO>
Operating Margin -50.20% — — TIE /operating-margins <GO>
Net Profit Margin -38.40% — — TIE /net-margins <GO>
Revenue Growth (YoY) 15.00% — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 0.52 — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 5/9 2/9 +3.00 ZLAB /piotroski-score <GO>
Options Implied Move & Put/Call Skew ACTIVE — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 40.3 69.8 -29.56 VRDN /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $2.51B $2.81B -$299.4M VRDN /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR ZLAB REV VRDN REV ZLAB GROSS % VRDN GROSS % ZLAB FCF VRDN FCF
FY 2025 $457.2M $0 58.3% — -$158.9M -$276.9M
FY 2024 $397.6M $0 63.0% — -$220.5M -$232.8M
FY 2023 $266.7M $0 — — -$198.2M -$184.2M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ZLAB // BETA —
VRDN // BETA —